HLOSF (Healios KK) Tariff Resilience Score: 7/10 (As of Jul. 03, 2026)


HLOSF Healios KK HLOSF
57 GF Score
Price $1.80
GF Value $0.33
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Healios KK Tariff Resilience Score?

Healios KK HLOSF 57 Tariff Resilience Score is 7 as of Jul. 03, 2026. GuruFocus rates HLOSF with a GF Score™ of 57/100 and a GF Value™ of $0.33 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,373 Biotechnology companies, Healios KK ranks better than 90.39% on this metric.

Healios KK has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Healios KK has Biotechnology firm with some exposure to tariffs on imported raw materials. However, its innovative products and potential for industry-specific exemptions provide a buffer against tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Healios KK might have Highly Resilient.

Healios KK  (OTCPK:HLOSF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Healios KK Tariff Resilience Score Related Terms

HLOSF vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Healios KK's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Healios KK Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Healios KK's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Healios KK's Tariff Resilience Score falls into.


HLOSF
57GF Score
Healios KK HLOSF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Healios KK (HLOSF) has a Tariff Resilience Score of 7 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Healios KK ranks #132 out of 1373 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Healios KK's Tariff Resilience Score too high?
Healios KK's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Healios KK's value of 7 is 75% above this industry median. Based on the distribution chart, Healios KK ranks #132 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Healios KK has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Healios KK ranks #132 out of 1373 companies for Tariff Resilience Score. This places Healios KK in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Healios KK's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healios KK's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healios KK's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (HLOSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.33, compared to a current price of $1.80 — trading 445.5% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Healios KK's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Healios KK (HLOSF), the current Tariff Resilience Score is 7 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healios KK (HLOSF) Overvalued in 2026?

Based on GuruFocus' analysis, Healios KK stock appears to be overvalued. The current stock price of $1.80 is trading 445.5% above its estimated GF Value™ of $0.33. GuruFocus considers Healios KK to be Significantly Overvalued.

Key valuation signals for HLOSF:

  • Tariff Resilience Score: 7
  • GF Value™: $0.33 vs. price of $1.80 (445.5% above fair value)
  • GF Score™: 57/100 with 5 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1373)

No single metric tells the full story. See the HLOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healios KK Business Description

Other Exchanges 4593:Japan6VX:Germany
Address 1-1-2 Yurakucho, Hibiya Mitsui Tower 12Floor, Work Styling, Chiyoda-ku, Tokyo, JPN, 100-0006
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
57GF Score

Get the complete analysis for HLOSF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.80
Price
$0.33
GF Value